MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

88.13 1.44

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

86.42

Максимум

89.56

Ключови измерители
By Trading Economics
Приходи	5.4M -48M
Продажби	6M 57M
Марж на печалбата	-82.974
Служители	414
EBITDA	5.1M -43M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+76.97% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.2B 5.3B
Предишно отваряне	86.69
Предишно затваряне	88.13

Настроения в новините

By Acuity

58%

42%

295 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.04.2026 г., 22:56 ч. UTC

Значими събития в новините

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1.04.2026 г., 20:50 ч. UTC

Придобивния, сливания и поглъщания

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1.04.2026 г., 23:55 ч. UTC

Пазарно говорене

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1.04.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1.04.2026 г., 23:23 ч. UTC

Значими събития в новините

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1.04.2026 г., 23:07 ч. UTC

Печалби

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1.04.2026 г., 23:02 ч. UTC

Значими събития в новините

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1.04.2026 г., 23:00 ч. UTC

Значими събития в новините

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1.04.2026 г., 23:00 ч. UTC

Значими събития в новините

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1.04.2026 г., 23:00 ч. UTC

Значими събития в новините

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1.04.2026 г., 22:39 ч. UTC

Печалби

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1.04.2026 г., 22:08 ч. UTC

Пазарно говорене

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1.04.2026 г., 22:00 ч. UTC

Значими събития в новините

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1.04.2026 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1.04.2026 г., 21:31 ч. UTC

Значими събития в новините

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

1.04.2026 г., 20:38 ч. UTC

Печалби

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1.04.2026 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1.04.2026 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1.04.2026 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1.04.2026 г., 20:13 ч. UTC

Придобивния, сливания и поглъщания

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1.04.2026 г., 20:07 ч. UTC

Пазарно говорене

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1.04.2026 г., 20:07 ч. UTC

Придобивния, сливания и поглъщания

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

76.97% нагоре

12-месечна прогноза

Среден 136.71 USD 76.97%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

295 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.